In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med Izervay has nabbed a much-needed label update from the FDA. The agency lifted ...
In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area Study results found no ...
Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression TOKYO, Oct. 8, 2025 ...
Gaining FDA approval last month for its geographic atrophy (GA) drug Izervay put Astellas on a collision course with Apellis and its GA treatment Syfovre, which was endorsed by the U.S. regulator in ...
(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) announced positive 24-month results from the Phase 3 GATHER2 clinical trial evaluating the efficacy and safety of Izervay (avacincaptad pegol ...
(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) announced results from the GATHER2 Phase 3 clinical trial, demonstrating Izervay (avacincaptad pegol intravitreal solution) continued to reduce the rate ...
NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the U.S. Centers for Medicare and Medicaid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback